{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Fate Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"FATE"},"Address":{"label":"Address","value":"3535 GENERAL ATOMICS COURT,SUITE 200, SAN DIEGO, California, 92121, United States"},"Phone":{"label":"Phone","value":"+1 858 875-1800"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients."},"CompanyUrl":{"label":"Company Url","value":"https://www.fatetherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bahram Valamehr","title":"Chief Research & Development Officer"},{"name":"J. Scott Wolchko","title":"President, Chief Executive Officer, CFO & CAO"},{"name":"Wen Bo Wang","title":"Senior Vice President-Technical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}